Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2745137 | 0.89 | CALM1 (0.55) | BCL2BCL2L1CALM1ALOX5MEN1 | |
| SCHEMBL7390204 | 0.79 | BCL2 (0.57) | BCL2BCL2L1CALM1ALOX5MEN1 | |
| SCHEMBL1773099 | 0.78 | HTR2A (0.56) | BCL2BCL2L1TSHRCALM1ALOX5 | |
| SCHEMBL5105991 | 0.72 | CYP2A6 (0.52) | BCL2L1TSHRALOX5KMT2ACYP2A6 | |
| SCHEMBL1244097 | 0.72 | CALM1 (0.41) | BCL2BCL2L1TSHRCALM1ALOX5 | |
| SCHEMBL11401184 | 0.71 | BCL2 (0.47) | BCL2BCL2L1TSHRCALM1ALOX5 | |
| SCHEMBL28330365 | 0.71 | BCL2 (0.52) | BCL2BCL2L1TSHRCALM1ALOX5 | |
| SCHEMBL972711 | 0.69 | CALM1 (0.69) | BCL2BCL2L1CALM1ALOX5MEN1 | |
| SCHEMBL5109182 | 0.68 | TSHR (0.43) | BCL2BCL2L1TSHRCALM1CYP2A6 | |
| SCHEMBL10524083 | 0.68 | BCL2 (0.44) | BCL2BCL2L1TSHRCALM1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342116-B2 | Process for producing heterocyclic aldehyde | KOEI CHEMICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | KOEI CHEMICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | ADH1C, ADH1A, AOX1 | BCL2 2718/4885BCL2L1 2298/4885TSHR 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.